Projekt · Dnr 2004-00790 · Källa: Vinnova
HIV peptides linked to cholera toxin B subunit, E! 3421 HIVVAC
- Koordinator
- CRUCELL SWEDEN AB, SBL Vaccin Aktiebolag
- Projekttid
- 2004-07-01 till 2007-12-31 (avslutat)
- Beviljat bidrag
- 3 000 000 SEK
- Diarienummer
- 2004-00790
Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.
Liknande
-
Improved, affordable single strain whole cell-B subunit oral cholera vaccine
Göteborgs universitet · 2017-06-01 · 5 950 000 SEK · Projekt
The goal has been to develop an improved, thermostable and affordable enterocoated capsule oral cholera vaccine (OCV), "Hillchol-B", based on lyophilized formalin-inactivated serotype Hikojima bacteria and recombinantly produced cholera toxin B subunit (rCTB). This has been accomplished at lab scale…
-
Preparedness and supply of pandemic influenza vaccine
Folkhälsomyndigheten · 2025-08-26 · 1 000 000 000 SEK · Upphandling
The Public Health Agency of Sweden invites tenderers to request to participate to tender for the provision of services for preparedness and supply of pandemic influenza vaccine. The goal is to award an Advanced Purchase Agreement (APA) to two or more suppliers, to be responsible for the supply and d…
-
Innovative Strategy for Targeted Delivery of Precision Medicine Drugs (INSPIRE)
Uppsala Therapeutics AB · 2021-05-01 · 1 918 560 SEK · Projekt
The aim of the project was to synthesize chemically modified oligonucleotides that are sensitive to stimuli like alkaline phosphatase and esterase. We have developed esterase-sensitive drug-siRNA conjugates and alkaline-sensitive chemically modified siRNA and DisiRNA. All our siRNAs are functional i…
-
OJ/2023/DPR/26575 - External quality assessment of antimicrobial susceptibility testing for Salmonella and Campylobacter - Lot 1: AST EQA for Salmonella enterica - Lot 2: AST EQA for Campylobacter spp.
European Centre for Disease Prevention and Control · 2024-01-19 · sista anbudsdag 2024-02-29 · 695 000 EUR · Upphandling
Lot 1 covers the organisation of an EQA exercise for phenotypic and genotypic antimicrobial susceptibility testing including detection and confirmation of ESBL-, acquired AmpC, and carbapenemase-producing Salmonella enterica Lot 2 covers the organisation of an EQA exercise for species identification…
-
E!11284, P-CALPRO, GeticaAB
GETICA AB · 2017-09-15 · 3 384 248 SEK · Projekt
The Calprotectin assay has been has been designed, verified and validated in peer reviewed journals and has demonstrated the method and the reagent to be superior to procalcitonin, C-reactive protein in intensive care patients. Objectives: To assess the value of plasma calprotectin as an early marke…